{"paper_id":"6f464ee1-421f-48d6-960c-0052b5f5757f","body_text":"Abstract\nEndometriosis is a benign reproductive tract disease, characterized by ectopic implantation of endometrial cells with elevated proliferation and migration capacity outside the uterus, mainly in the pelvis. Despite its benign nature, a number of studies support the notion that endometriosis may represent the initial stage of a neoplastic process, especially in the ovary. In fact, endometriosis shares several common features with cancer, including the ability to evade apoptosis, cell migration and proliferation, implantation at distant sites, neovascularization, creating a microenvironment eluding the immune system. A possible genetic link has been suggested in recent studies, highlighting driver mutations in PIK3CA, KRAS, ARID1A, and other genes. However, the underlying molecular and cellular mechanisms are still not fully understood.\nEndometriosis-associated ovarian cancer (EAOC) represents a heterogeneous group of different types of cancer including clear cell carcinoma, endometrioid carcinoma, and seromucinous borderline tumor, arising from coexistent endometriosis. However, clinical studies show controversial results on the link between endometriosis and cancer. Furthermore, considering the discrepancy between the low prevalence of EAOC and the high frequency of endometriosis, the hypothesis that endometriosis represents an exclusive premalignant condition is yet to be fully demonstrated. Atypical phenotypes of ovarian endometriosis require an appropriate imaging evaluation, but there are no conclusive data indicating that a specific screening protocol or the prophylactic removal of endometriosis lesions reduces the risk of EAOC. Further studies are needed to adequately explore clinical and basic science data on the link between endometriosis and cancer.\nAccess this chapter\nTax calculation will be finalised at checkout\nPurchases are for personal use only\nSimilar content being viewed by others\nReferences\nZondervan KT, Becker CM, Missmer SA. Endometriosis. N Engl J Med. 2020;382:1244–56.\nBulun SE, Yilmaz BD, Sison C, Miyazaki K, Bernardi L, Liu S, Kohlmeier A, Yin P, Milad M, Wei J. Endometriosis. Endocr Rev. 2019b;40:1048–79.\nZondervan KT, Becker CM, Koga K, Missmer SA, Taylor RN, Viganò P. Endometriosis. Nat Rev Dis Primers. 2018 Jul 19;4(1):9.\nWei JJ, William J, Bulun S. Endometriosis and ovarian cancer: a review of clinical, pathologic, and molecular aspects. Int J Gynecol Pathol. 2011;30:553–68.\nRuderman R, Pavone ME. Ovarian cancer in endometriosis: an update on the clinical and molecular aspects. Minerva Ginecol. 2017;69:286–94.\nMok SC, Kwong J, Welch WR, Samimi G, Ozbun L, Bonome T, Birrer MJ, Berkowitz RS, Wong KK. Etiology and pathogenesis of epithelial ovarian cancer. Dis Markers. 2007;23:367–76.\nSampson JA. Endometrial carcinoma of the ovary arising in endometrial tissue in that organ. Arch Surg. 1925;10:1–72.\nScott RB. Malignant changes in endometriosis. Obstet Gynecol. 1953;2:283–9.\nGrandi G, Toss A, Cortesi L, Botticelli L, Volpe A, Cagnacci A. The association between Endometriomas and ovarian Cancer: preventive effect of inhibiting ovulation and menstruation during reproductive life. Biomed Res Int. 2015;2015:751571.\nPearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 2012;13:385–94.\nVercellini P, Parazzini F, Bolis G, Carinelli S, Dindelli M, Vendola N, Luchini L, Crosignani PG. Endometriosis and ovarian cancer. Am J Obstet Gynecol. 1993;169:181–2.\nJimbo H, Yoshikawa H, Onda T, Yasugi T, Sakamoto A, Taketani Y. Prevalence of ovarian endometriosis in epithelial ovarian cancer. Int J Gynaecol Obstet. 1997;59:245–50.\nDawson A, Fernandez ML, Anglesio M, Yong PJ, Carey MS. Endometriosis and endometriosis-associated cancers: new insights into the molecular mechanisms of ovarian cancer development. Ecancermedicalscience. 2018;12:803.\nVercellini P, Viganò P, Buggio L, Makieva S, Scarfone G, Cribiù FM, Parazzini F, Somigliana E. Perimenopausal management of ovarian endometriosis and associated cancer risk: when is medical or surgical treatment indicated? Best Pract Res Clin Obstet Gynaecol. 2018;51:151–68.\nHeidemann LN, Hartwell D, Heidemann CH, Jochumsen KM. The relation between endometriosis and ovarian cancer - a review. Acta Obstet Gynecol Scand. 2014;93:20e31.\nSaavalainen L, Lassus H, But A, Tiitinen A, Härkki P, Gissler M, Pukkala E, Heikinheimo O. Risk of gynecologic Cancer according to the type of endometriosis. Obstet Gynecol. 2018;131:1095–102.\nWorley MJ, Welch WR, Berkowitz RS, Ng SW. Endometriosis-associated ovarian cancer: a review of pathogenesis. Int J Mol Sci. 2013;14:5367–79.\nKobayashi H, Sumimoto K, Kitanaka T, Yamada Y, Sado T, Sakata M, Yoshida S, Kawaguchi R, Kanayama S, Shigetomi H, Haruta S, Tsuji Y, Ueda S. Terao T ovarian endometrioma--risks factors of ovarian cancer development. Eur J Obstet Gynecol Reprod Biol. 2008;138:187–93.\nWang KC, Chang WH, Lee WL, Huang N, Huang HY, Yen MS, Guo CY, Wang PH. An increased risk of epithelial ovarian cancer in Taiwanese women with a new surgico-pathological diagnosis of endometriosis. BMC Cancer. 2014;14:831.\nModugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG, Goodman MT. Oral 920 contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with 921 and without endometriosis. Am J Obstet Gynecol. 2004;191:733–40.\nStewart LM, Holman CD, Aboagye-Sarfo P, Finn JC, Preen DB. Hart R in vitro fertilization, endometriosis, nulliparity and ovarian cancer risk. Gynecol Oncol. 2013;128:260–4.\nTorng PL. Clinical implication for endometriosis associated with ovarian cancer. Gynecol Minim Invasive Ther. 2017;6:152–6.\nLaGrenade A, Silverberg SG. Ovarian tumors associated with atypical endometriosis. Case Reports Hum Pathol. 1988;19:1080–4.\nHerreros-Villanueva M, Chen CC, Tsai EM, Er TK. Endometriosis-associated ovarian cancer: what have we learned so far? Clin Chim Acta. 2019;493:63–72.\nReis FM, Petraglia F, Taylor RN. Endometriosis: hormone regulation and clinical consequences of chemotaxis and apoptosis. Hum Reprod Update. 2013 Jul-Aug;19(4):406–18.\nAnglesio MS, Papadopoulos N, Ayhan A, Nazeran TM, Noë M, Horlings HM, Lum A, Jones S, Senz J, Seckin T, Ho J, Wu RC, Lac V, Ogawa H, Tessier-Cloutier B, Alhassan R, Wang A, Wang Y, Cohen JD, Wong F, Hasanovic A, Orr N, Zhang M, Popoli M, McMahon W, Wood LD, Mattox A, Allaire C, Segars J, Williams C, Tomasetti C, Boyd N, Kinzler KW, Gilks CB, Diaz L, Wang TL, Vogelstein B, Yong PJ, Huntsman DG, Shih IM. Cancer-associated mutations in endometriosis without Cancer. N Engl J Med. 2017;376:1835–48.\nBulun SE, Wan Y, Matei D. Epithelial mutations in endometriosis: link to ovarian Cancer. Endocrinology. 2019a;160:626–38.\nAyhan A, Mao TL, Seckin T, Wu CH, Guan B, Ogawa H, et al. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer. 2012;22:1310–5.\nYamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol. 2012;25:615–24.\nYamamoto S, Tsuda H, Takano M, Iwaya K, Tamai S, Matsubara O. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. J Pathol. 2011;225:189–94.\nSmith IN, Briggs JM. Structural mutation analysis of PTEN and its genotype-phenotype correlations in endometriosis and Cancer. Proteins. 2016;84:1625–43.\nGovatati S, Kodati VL, Deenadayal M, Chakravarty B, Shivaji S, Bhanoori M. Mutations in the PTEN tumor gene and risk of endometriosis: a case-control study. Hum Reprod. 2014;29:324–36.\nStewart CJ, Leung Y, Walsh MD, Walters RJ, Young JP, Buchanan DD. KRAS mutations in ovarian low-grade endometrioid adenocarcinoma: association with concurrent endometriosis. Hum Pathol. 2012;43:1177–83.\nRen F, Wang D, Jiang Y, Ren F. Epigenetic inactivation of hMLH1 in the malignant transformation of ovarian endometriosis. Arch Gynecol Obstet. 2012;285:215–21.\nHou Z, Sun L, Gao L, Liao L, Mao Y, Liu J. Cytokine array analysis of peritoneal fluid between women with endometriosis of different stages and those without endometriosis. Biomarkers. 2009;14:604–18.\nDarai E, Detchev R, Hugol D, Quang NT. Serum and cyst fluid levels of interleukin (IL)-6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours. Hum Reprod. 2003;18:1681–5.\nYilmaz BD, Bulun SE. Endometriosis and nuclear receptors. Hum Reprod Update. 2019;25:473–85.\nMonsivais D, Dyson MT, Yin P, Coon JS, Navarro A, Feng G, Malpani SS, Ono M, Ercan CM, Wei JJ, Pavone ME, Su E, Bulun SE. ERβ- and prostaglandin E2-regulated pathways integrate cell proliferation via Ras-like and estrogen-regulated growth inhibitor in endometriosis. Mol Endocrinol. 2014;28:1304–15.\nScutiero G, Iannone P, Bernardi G, Bonaccorsi G, Spadaro S, Volta CA, Greco P, Nappi L. Oxidative stress and endometriosis: a systematic review of the literature. Oxidative Med Cell Longev. 2017;2017:7265238.\nKajiyama H, Suzuki S, Yoshihara M, Tamauchi S, Yoshikawa N, Niimi K, Shibata K, Kikkawa F. Endometriosis and cancer. Free Radic Biol Med. 2019;133:186–92.\nLaschke MW, Giebels C, Menger MD. Vasculogenesis: a new piece of the endometriosis puzzle. Hum Reprod Update. 2011;17:628–36.\nKrálíčková M, Losan P, Vetvicka V. Endometriosis and cancer. Womens Health (Lond). 2014;10:591–7.\nLaschke MW, Menger MD. Basic mechanisms of vascularization in endometriosis and their clinical implications. Hum Reprod Update. 2018;24:207–24.\nRiccio LDGC, Santulli P, Marcellin L, Abrão MS, Batteux F, Chapron C. Immunology of endometriosis. Best Pract Res Clin Obstet Gynaecol. 2018;50:39–49.\nSuryawanshi S, Huang X, Elishaev E, Budiu RA, Zhang L, Kim S, Donnellan N, Mantia-Smaldone G, Ma T, Tseng G, Lee T, Mansuria S, Edwards RP, Vlad AM. Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res. 2014;20:6163–74.\nExacoustos C, Manganaro L, Zupi E. Imaging for the evaluation of endometriosis and adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2014;28:655e81.\nGuerriero S, Ajossa S, Mais V, et al. The diagnosis of endometriomas using colour Doppler energy imaging. Hum Reprod. 1998;6:1691–5.\nVan Holsbeke C, Van Calster B, Guerriero S, Savelli L, Paladini D, Lissoni AA, Czekierdowski A, Fischerova D, Zhang J, Mestdagh G, Testa AC, Bourne T, Valentin L, Timmerman D. Endometriomas: their ultrasound characteristics. Ultrasound Obstet Gynecol. 2010;35:730–40.\nGuerriero S, Condous G, van den Bosch T, Valentin L, Leone FP, Van Schoubroeck D, Exacoustos C, Installé AJ, Martins WP, Abrao MS, Hudelist G, Bazot M, Alcazar JL, Gonçalves MO, Pascual MA, Ajossa S, Savelli L, Dunham R, Reid S, Menakaya U, Bourne T, Ferrero S, Leon M, Bignardi T, Holland T, Jurkovic D, Benacerraf B, Osuga Y, Somigliana E, Timmerman D. Systematic approach to sonographic evaluation of the pelvis in women with suspected endometriosis, including terms, definitions and measurements: a consensus opinion from the International Deep Endometriosis Analysis (IDEA) group. Ultrasound Obstet Gynecol. 2016a;48:318–32.\nGuerriero S, Van Calster B, Somigliana E, Ajossa S, Froyman W, De Cock B, Coosemans A, Fischerová D, Van Holsbeke C, Alcazar JL, Testa AC, Valentin L, Bourne T, Timmerman D. Age-related differences in the sonographic characteristics of endometriomas. Hum Reprod. 2016b;31:1723–31.\nTesta AC, Timmerman D, Van Holsbeke C, Zannoni GF, Fransis S, Moerman P, Vellone V, Mascilini F, Licameli A, Ludovisi M, Di Legge A, Scambia G, Ferrandina G. Ovarian cancer arising in endometrioid cysts: ultrasound findings. Ultrasound Obstet Gynecol. 2011;38:99–106.\nNezhat FR, Apostol R, Nezhat C, Pejovic T. New insights in the pathophysiology of ovarian cancer and implications for screening and prevention. Am J Obstet Gynecol. 2015;213:262–7.\nTanase Y, Kawaguchi R, Takahama J, Kobayashi H. Factors that differentiate between endometriosis-associated ovarian Cancer and benign ovarian endometriosis with mural nodules. Magn Reson Med Sci. 2018;17:231–7.\nHe ZX, Shi HH, Fan QB, Zhu L, Leng JH, Sun DW, et al. Predictive factors of ovarian carcinoma for women with ovarian endometrioma aged 45 years and older in China. J Ovarian Res. 2017;10:45.\nKuo HH, Huang CY, Ueng SH, Huang KG, Lee CL, Yen CF. Unexpected epithelial ovarian cancers arising from presumed endometrioma: a 10-year retrospective analysis. Taiwan J Obstet Gynecol. 2017;56:55–61.\nMoro F, Magoga G, Pasciuto T, Mascilini F, Moruzzi MC, Fischerova D, Savelli L, Giunchi S, Mancari R, Franchi D, Czekierdowski A, Froyman W, Verri D, Epstein E, Chiappa V, Guerriero S, Zannoni GF, Timmerman D, Scambia G, Valentin L, Testa AC. Imaging in gynecological disease (13): clinical and ultrasound characteristics of endometrioid ovarian cancer. Ultrasound Obstet Gynecol. 2018;52:535–43.\nDochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019;12:28.\nMoga MA, Bălan A, Dimienescu OG, Burtea V, Dragomir RM, Anastasiu CV. Circulating miRNAs as biomarkers for endometriosis and endometriosis-related ovarian Cancer-an overview. J Clin Med. 2019;8:735.\nSuryawanshi S, Vlad AM, Lin HM, Mantia-Smaldone G, Laskey R, Lee M, Lin Y, Donnellan N, Klein-Patel M, Lee T, Mansuria S, Elishaev E, Budiu R, Edwards RP, Huang X. Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res. 2013;19:1213–24.\nTaniguchi F. New knowledge and insights about the malignant transformation of endometriosis. J Obstet Gynaecol Res. 2017;43:1093.\nRossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS. Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery. Cancer Causes Control. 2008;19:1357e64.\nMelin AS, Lundholm C, Malki N, Swahn ML, Sparèn P, Bergqvist A. Hormonal and surgical treatments for endometriosis and risk of epithelial ovarian cancer. Acta Obstet Gynecol Scand. 2013;92:546e54.\nNational Institute for Health and Care Excellence. Endometriosis: diagnosis and management. NICE guideline NG73. September 2017. https://www.nice.org.uk/guidance/ng73/evidence/full-guideline-pdf-4550371315.\nWilbur MA, Shih IM, Segars JH, Fader AN. Cancer implications for patients with endometriosis. Semin Reprod Med. 2017;35:110–6.\nPaik ES, Kim TJ, Choi CH, Kim BG, Bae DS, Lee JW. Clinical outcomes of patients with clear cell and endometrioid ovarian cancer arising from endometriosis. J Gynecol Oncol. 2018;29:e18.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nEditor information\nEditors and Affiliations\nRights and permissions\nCopyright information\n© 2021 International Society of Gynecological Endocrinology\nAbout this chapter\nCite this chapter\nVannuccini, S., Clemenza, S., Petraglia, F. (2021). Endometriosis and Cancer: Prevention and Diagnosis. In: Genazzani, A.R., Nisolle, M., Petraglia, F., Taylor, R.N. (eds) Endometriosis Pathogenesis, Clinical Impact and Management. ISGE Series. Springer, Cham. https://doi.org/10.1007/978-3-030-57866-4_13\nDownload citation\nDOI: https://doi.org/10.1007/978-3-030-57866-4_13\nPublished:\nPublisher Name: Springer, Cham\nPrint ISBN: 978-3-030-57865-7\nOnline ISBN: 978-3-030-57866-4\neBook Packages: MedicineMedicine (R0)","source_license":"CC0","license_restricted":false}